Combined thyroid extract and levothyroxine for thyroid cancer
Part of Hormones & metabolism clinical trials.
This trial tests whether a combination of two thyroid hormone medications can better suppress TSH in people with differentiated thyroid cancer. It may help those who have not reached their TSH target with standard levothyroxine alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have differentiated thyroid cancer confirmed by tissue sample (biopsy).
- You are at intermediate or high risk of the cancer coming back.
- You are 18 years or older (and between 18 and 70 if in stage 2 of the trial).
- Your TSH is still above the target level even though your free T4 is in the high-normal range.
- You have not had a stomach surgery that affects absorption, and you do not have certain gut conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for patients with a small thyroid cancer (1 cm or less) that is not aggressive. It tests whether taking thyroid hormone to keep TSH low is necessary during active surveillance (watching the cancer closely instead of removing it right away).
This study compares two methods to lower a hormone called TSH that can make thyroid cancer grow. It is for people with advanced thyroid cancer who live in Alberta and can come to Edmonton for treatment.
This trial tests if an existing drug (used for other conditions) can help people with advanced thyroid cancer who have run out of treatment options. You'll get a new drug and be monitored to see if it shrinks your cancer or slows it down.
This trial tests a combination of two drugs (sinibolimab and lenvatinib) given before surgery. The goal is to shrink advanced thyroid cancer that cannot be fully removed otherwise, so that surgery can be more successful.
This trial tests whether a medicine called recombinant human thyroid stimulating hormone (rhTSH) can help prepare your body for radioactive iodine (131I) treatment, which aims to destroy any remaining or spreading thyroid cancer cells. It may be a good option if your thyroid cancer has come back or spread and you are able to have radioactive iodine therapy.
This trial tests if adding a second thyroid hormone (T3) to standard levothyroxine (T4) can better relieve persistent hypothyroidism symptoms like fatigue or brain fog. You may qualify if you still have symptoms despite being on a stable dose of levothyroxine.
Hear when a new Intermediate-to-High Risk Differentiated Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.